Regional Research Centre for Respiratory Medicines and Tropical Diseases

Browse:

/content/moderna-corp-aem/en-au/regional-research-centre

Fellowship

/content/moderna-corp-aem/en-au/fellowship

tab1

Infectious and tropical diseases hold significant importance in Australia and the surrounding region due to their potential to impact public health, economies, and overall well-being. mRNA science has the potential to overcome many of these diseases.

The Regional Research Centre fosters the Australian mRNA research ecosystem to deliver mRNA-based solutions to the world.

secondary

Building mRNA Capability Partnerships

The Regional Research Centre has long term capability based collaborative relationships with key stakeholders in Australian mRNA Research and Development (R&D) and in areas of high unmet medical need.

left

Monash-Moderna Quantitative Pharmacology Accelerator (MMQPA)

The MMQPA sees the Regional Research Centre partner with Monash University to drive advancements in mRNA medicines, including therapeutics and vaccines, through a strategic 5-year, $3 million investment by Moderna, and substantial in-kind contributions to the collaboration from Moderna and MIPS.

LEARN MORE >

mRNA Platform Incubator Network (mPIN)

The mPIN is a pioneering collaboration with key Australian organisations with specialist expertise in translational and pharmaceutical science, early phase clinical trials and regulatory science. It aims to advance mRNA medicine, foster scientific excellence in clinical translation in Australia and further the therapeutic potential of the mRNA platform.

The mPIN brings together experts from Monash University and Monash Institute of Pharmaceutical Sciences (MIPS), the Peter Doherty Institute of Infection and Immunity – a joint venture of The University of Melbourne and The Royal Melbourne Hospital, Peter MacCallum Cancer Centre, the Murdoch Research Children’s Institute and Doherty Clinical Trials Limited.

LEARN MORE >

Delivering Research Excellence

We deliver excellence in the design and execution of clinical trials, build capability and deliver research and translational projects and data partnerships.

left

Clinical Trials

Moderna has multiple clinical trials running in Australia, both as part of global trials and as Australia only studies. Clinical trial sites are spread across most states and territories in Australia and involve researchers, clinicians and patients in studies trialing medicines for infectious diseases such as COVID, flu and RSV, multiple cancer therapies and rare diseases.

mRNA access program

Moderna’s mRNA access program aims to accelerate the creation of new vaccines using mRNA technology in collaboration with global partners. Through the program, researchers beyond Moderna can take advantage of the flexibility afforded by our platform to develop novel mRNA medicines for emerging and neglected infectious diseases.

mRNA regulatory science and policy

The Regional Research Centre holds regular roundtables with leading Australian scientists, clinicians and state and federal government stakeholders. Discussions from some of these roundtables have led to a peer-reviewed publication on "The Platform Technology Approach to mRNA Product Development and Regulation", aiming to advance regulatory science and policy to enable more efficent access to mRNA vaccines and therapeutics.

Driving Innovation

We drive innovation by setting industry standards and inspiring breakthrough scientific advancements.

left

Moderna Australia Fellowship Program

The fellowship program is designed to support Australia-based mRNA research that over time can translate into clinical studies and ultimately new medicines.

LEARN MORE >